Loading
institutionsInstitution
UNC Lineberger Comprehensive Cancer Center
Where Charles Perou defined the PAM50 intrinsic subtypes of breast cancer; a public university centre with in-house CAR-T manufacturing.
Overview
NCI-designated since 1975 and comprehensive since 1990, UNC Lineberger is a public-university cancer centre with a statewide remit across North Carolina. Charles Perou's intrinsic subtypes and the PAM50 assay reshaped breast cancer classification; Norman Sharpless, later NCI director, worked on CDK4/6 and cellular senescence here and co-founded G1 Therapeutics. Gianpietro Dotti and Barbara Savoldo run one of the few academic in-house CAR-T programmes, and Ethan Basch's patient-reported outcome trials changed how symptoms are monitored during chemotherapy. Blossom Damania and Dirk Dittmer lead research on Kaposi sarcoma herpesvirus and virus-associated cancers.
Location
Chapel Hill, NC, US
Type
cancer center · University of North Carolina at Chapel Hill
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
NCI designation
comprehensive
OnCo score
#62 · 47 points (0 Newsweek + 15 NCI + 32 from 16 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-17.
Matched to UNC Lineberger Comprehensive Cancer Center, including child institutions. 434 works · 6,795 citations · 76% open access · 11% clinical trials · 2% reviews.
Oncology works per year
1302022
1072023
932024
662025
382026
Most works
- Lisa A. Carey40 works
- Charles M. Perou26 works
- Natalie S. Grover25 works
- Gianpietro Dotti21 works
- Aleix Prat21 works
- Ethan Basch21 works
- Stephanie B. Wheeler17 works
- Katherine E. Reeder‐Hayes16 works
- Barbara Savoldo15 works
- Javier Cortés14 works
Most cited
- Breast cancer subtyping (PAM50)
- Academic CAR-T
- Patient-reported outcomes
- Viral oncology
Charles M. Perou
Professor of Genetics and Pathology, UNC Lineberger Comprehensive Cancer Center
Breast cancer genomicsIntrinsic subtypesPAM50
Defined the molecular subtypes of breast cancer (luminal, HER2-enriched, basal-like) that clinicians now use every day.
Ethan Basch
Chief of Medical Oncology and Physician-in-Chief, UNC Lineberger Comprehensive Cancer Center
Patient-reported outcomesSymptom monitoringHealth outcomes research
Proved that letting patients report symptoms electronically during chemotherapy improves quality of life and survival.
Robert L. Ferris
Head and neck surgeon and Director, UNC Lineberger Comprehensive Cancer Center
Head and neck cancerTumour immunologyTransoral surgery
Surgeon and immunologist who led CheckMate 141, the trial that made nivolumab the first drug to lengthen survival in head and neck cancer after platinum failure, and E3311 on transoral surgery for HPV-positive throat cancer.
methodsClinical Cancer Research 2020188 citations
Purity Independent Subtyping of Tumors (PurIST), a clinically robust, single-sample classifier for tumor subtyping in pancreatic cancer
PurIST is the assay form of the Moffitt subtypes and the tool prospective subtype-stratified trials use.
basicNature Genetics 20151,841 citations
Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma
The classical versus basal-like split, later tied to GATA6 expression and to chemotherapy response, is the subtype scheme most likely to reach the clinic; the stromal subtypes are why the desmoplastic stroma is treated as a partner in the disease rather than inert scar.
observationalJAMA 2006changed practice2,791 citations
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
The paper that made race a biological as well as a social variable in triple-negative breast cancer, and the reason the US disparity is described as roughly twice the incidence in Black women; the UK POSH study later found a smaller but real excess.
basicNature 2000changed practice11,239 citations
Molecular portraits of human breast tumours
The origin of the intrinsic subtypes and of the word basal-like; triple-negative breast cancer is the clinical shadow of this molecular group, though the two overlap imperfectly.
Similar pages
- Key paperGene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
Shares Molecular portraits of human breast tumours, Charles M. Perou, PAM50 / intrinsic subtypes, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem.
- Key paperRepeated observation of breast tumor subtypes in independent gene expression data sets
Shares Molecular portraits of human breast tumours, Charles M. Perou, PAM50 / intrinsic subtypes, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem.
- Key paperBasch: asking patients to report symptoms online during chemotherapy improved survival
Shares Ethan Basch, Patients lack understanding, navigation and agency, Toxicity and quality of life are undervalued.
- Key paperEthnicity and outcome of young breast cancer patients in the United Kingdom: the POSH study
Shares Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- Key paperGermline BRCA1 mutations and a basal epithelial phenotype in breast cancer
Shares Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC).
- Key paperDescriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry
Shares Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC).
- IdeaMake skipping radiotherapy the default for very low-risk breast cancer
Shares PAM50 / intrinsic subtypes, Toxicity and quality of life are undervalued, HR-positive / HER2-negative breast cancer.
- Key paperComprehensive molecular portraits of human breast tumours
Shares Charles M. Perou, PAM50 / intrinsic subtypes, Triple-negative breast cancer (TNBC).
cancers
technologies
institutions
terms
roadmaps
Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance questionTriple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem
people
bottlenecks
key papers
Molecular portraits of human breast tumoursPurity Independent Subtyping of Tumors (PurIST), a clinically robust, single-sample classifier for tumor subtyping in pancreatic cancerRace, breast cancer subtypes, and survival in the Carolina Breast Cancer StudyVirtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma